UTI – Quo Vadis? New Alternatives to Treat Uncomplicated Urinary Tract Infections

##plugins.themes.bootstrap3.article.sidebar##

PDF (Українська)
Published: Apr 30, 2020
DOI: https://doi.org/10.30841/2307-5090.1.2020.205152
Keywords:
uncomplicated urinary tract infection, urinary tract infection, Canephron® N, Fosfomycintrometamol, antibiotic resistance, acute cystitis symptom score, global prevalence study on infections inurology,

##plugins.themes.bootstrap3.article.main##

K. G. Naber
Technical University of Munich, Germany
Z. Tandogdu
Oslo University, University College London Hospitals, Norway
B. Köves
Jahn Ferenc South Pest Teaching Hospital, Hungary
G. Bonkat
University Basel, Alta Uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry (COB), Switzerland
F. Wagenlehner
Justus-Liebig University of Giessen, Germany

Abstract

Urinary tract infections (UTI) are one of the most common problems in urology clinics. The European Association of Urology (EAU) has been pioneering in its efforts to disseminate the latest clinical findings through the organization of the annual EAU congresses. At this year’s congress (EAU Barcelona 2019), various satellite symposia were organized, focusing on specific issues in the field of urology. “UTI – quo vadis? New alternatives to treat uncomplicated urinary tract infections” was one of the industry-sponsored symposia, organized with the aim of evaluating the current scenario and also throwing light on the paradigm shift in the treatment of acute, uncomplicated lower urinary tract infections (uUTI). Several interlinking topics were presented during this symposium. The topics covered antibiotic resistance, involving a presentation of the current data from the Global Prevalence Study on Infections in Urology (GPIU-study). This discussion was followed by case reports on the impact of antibiotic resistance on the management of patients with UTI/uUTI and treatment options for UTI/uUTI according to current guidelines. The highlight of the symposium was the presentation of very recent data from a gold standard phase III clinical trial (double-blind, double-dummy randomized study), demonstrating the non-inferiority of a herbal medicine( BNO 1045) versus antibiotic therapy (fosfomycin trometamol (FT), as a single dose = 3 g) for the treatment of acute, uncomplicated cystitis.

##plugins.themes.bootstrap3.article.details##

How to Cite
Naber, K. G., Tandogdu, Z., Köves, B., Bonkat, G., & Wagenlehner, F. (2020). UTI – Quo Vadis? New Alternatives to Treat Uncomplicated Urinary Tract Infections. Health of Man, (1), 19–25. https://doi.org/10.30841/2307-5090.1.2020.205152
Issue
No. 1 (2020)
Section
Topical issues
Copyright (c) 2020 K. G. Naber, Z. Tandogdu, B. Köves, G. Bonkat, F. Wagenlehner

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biographies

K. G. Naber, Technical University of Munich

Kurt G. Naber,

Department of Urology

Z. Tandogdu, Oslo University, University College London Hospitals

Zafer Tandogdu,

Institute for Clinical Medicine at the Oslo University,

Department of Urology at the University College London Hospitals

B. Köves, Jahn Ferenc South Pest Teaching Hospital

Bela Köves,

Department of Urology

G. Bonkat, University Basel, Alta Uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry (COB)

Gernot Bonkat

F. Wagenlehner, Justus-Liebig University of Giessen

Florian Wagenlehner,

Clinic for Urology, Pediatric Urology and Andrology

References

Antimicrobial Resistance: tackling a crisis for the health and wealth of nations. The review on antimicrobial resistance chaired by Jim O’Neill. 2014.

de Kraker, Marlieke EA, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016;13(11): e1002184.

Wagenlehner F, et al. The global prevalence of infections in urology (GPUI) study: a worldwide surveillance study in urology patients. Eur Urol Focus. 2016;2(4):345–7 gpiu.esiu.org/.

Wagenlehner FM, et al. Non-antibiotic herbal therapy (BNO 1045) versus antibiotic therapy (Fosfomycin Trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre, non-inferiority phase III trial. Urol Int. 2018;101(3):327–36.

Beahm NP, Nicolle LE, Bursey A, Smyth DJ, Tsuyuki RT. The assessment and management of urinary tract infections in adults: guidelines for pharmacists. Can Pharm J (Ott). 2017;150(5):298–305. https://doi.org/10.1177/ 1715163517723036 Published 2017 Jul 31.

Ernst EJ, Ernst ME, Hoehns JD, Bergus GR. Women’s quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health Qual Life Outcomes. 2005;3:45. https://doi.org/10.1186/ 1477-7525-3-45 Published 2005 Jul 27.

Alidjanov JF, Abdufattaev UA, Makhsudov SA, Pilatz A, Akilov FA, Naber KG, Wagenlehner FM. New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: acute cystitis symptom score. Urol Int. 2014;92:230–6. https://doi.org/10.1159/000356177.

Nicolle LE. The paradigm shift to nontreatment of asymptomatic bacteriuria. Pathogens. 2016;5(2):38. https://doi.org/10.3390/ pathogens5020038 Published 2016 Apr 19.

European Association of Urology. EAU guidelines on urological infections. 2019. uroweb.org/guideline/urologicalinfections

Thomas-White K, Brady M, Wolfe AJ, Mueller ER. The bladder is not sterile: history and current discoveries on the urinary microbiome. Curr Bladder

Kogan MI, Naboka YL, Ibishev KS, Gudima IA, Naber KG. Human urine is not sterile – shift of paradigm. Urol Int. 2015;94(4):445–52.

Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010 Dec.;7(12):653–60.

Knottnerus BJ, Geerlings SE, Moll van Charante EP, ter Riet G. Women with symptoms of uncomplicated urinary tract infection are often willing to delay antibiotic treatment: a prospective cohort study. BMC Fam Pract. 2013;14:71. Published 2013 May 31. https://doi.org/10.1186/1471-2296-14-71.

Ildikó G, Jutta B, Kochen Michael M, Guido S, Karl W, Eva H-P, et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015;351:h6544.

Bleidorn J, Gágyor I, Kochen MM, Wegscheider K, Hummers-Pradier E. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? – results of a randomized controlled pilot trial. BMC Med. 2010;8:30-7. https://doi.org/10.1186/1741-7015-8-30.

Vik I, Bollestad M, Grude N, Bñrheim A, Damsgaard E, Neumark T, et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women. A double-blind, randomized non-inferiority trial. PLoS Med. 2018; 15(5):e1002569 https://doi.org/10.1371/journal.pmed.1002569.

Kronenberg, et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ. 2017;359:j4784 https://doi.org/10.1136/bmj.j4784.

Fleming A. Penicillin’s finder assays its future. New York Times. 1945;26:21.

Künstle G et al.. Efficacy of Canephron N against bacterial adhesion, inflammation and bladder hyperactivity. European Association of Urology Congress, Milan 2013, Congress poster 671.2013.

Nausch B et al.. Canephron N reduced nociception in experimental cystitis and inhibited the pain-related targets NK1 receptor and ASIC1a. Internationale Tagung Phytotherapie 2014, Winterthur, Schweiz, 18.-21. Juni 2014. Congress poster. 2014.

Brenneis C et al.. Spasmolytic activity of Canephron N on the contractility of isolated urinary bladder. International Congress of Ethnopharmacology, Graz, Austria, Congress poster. 2012.

Alidjanov JF, et al. The acute cystitis symptom score for patient-reported outcome assessment. Urol Int. 2016;97(4):402–9.